[{"from": "human", "value": "Describe this molecule. [C][S@][=Branch1][C][=O][C][C][O][C][=C][Branch2][Branch1][N][C][=C][Branch2][Branch1][=Branch1][C][=Branch1][Ring2][=C][Ring1][=Branch1][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][C][N][C][=C][Branch2][Ring1][Branch2][C][=N][C][=Branch1][N][=N][N][Ring1][Branch1][C][=Branch1][Ring2][=N][Ring1][=Branch2][N][C][=C][C][=C][O][Ring1][Branch1][S][C][Ring2][Ring1][C][=O][F][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, inupadenant selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression."}]